Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis
Go back to Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 508.34 -8 (1.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $516.34 | 52 Week High | $134.71 | |||
| Open | $516.34 | 52 Week Low | $73.31 | |||
| Day High | $518.10 | P/E | N/A | |||
| Day Low | $505.01 | EPS | $-1.98 | |||
| Volume | 2,434,829 | |||||
